Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
346.98
+5.13 (1.50%)
At close: Jan 29, 2026, 4:00 PM EST
345.82
-1.16 (-0.33%)
Pre-market: Jan 30, 2026, 4:15 AM EST
Elevance Health Stock Forecast
Stock Price Forecast
The 17 analysts that cover Elevance Health stock have a consensus rating of "Buy" and an average price target of $391.94, which forecasts a 12.96% increase in the stock price over the next year. The lowest target is $297 and the highest is $485.
Price Target: $391.94 (+12.96%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 6 | 6 | 6 | 7 |
| Hold | 3 | 3 | 6 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 17 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $414 → $396 | Strong Buy | Maintains | $414 → $396 | +14.13% | Jan 29, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $398 → $414 | Strong Buy | Maintains | $398 → $414 | +19.32% | Jan 22, 2026 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $425 | Hold → Buy | Upgrades | $425 | +22.49% | Jan 8, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $403 → $424 | Buy | Maintains | $403 → $424 | +22.20% | Jan 7, 2026 |
| Barclays | Barclays | Buy Maintains $385 → $404 | Buy | Maintains | $385 → $404 | +16.43% | Jan 5, 2026 |
Financial Forecast
Revenue This Year
206.86B
from 199.13B
Increased by 3.88%
Revenue Next Year
216.16B
from 206.86B
Increased by 4.49%
EPS This Year
27.23
from 25.21
Increased by 8.02%
EPS Next Year
31.47
from 27.23
Increased by 15.56%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 224.9B | 231.1B | ||
| Avg | 206.9B | 216.2B | ||
| Low | 193.6B | 199.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 12.9% | 11.7% | ||
| Avg | 3.9% | 4.5% | ||
| Low | -2.8% | -3.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 31.03 | 39.05 | |||
| Avg | 27.23 | 31.47 | |||
| Low | 24.01 | 27.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 23.1% | 43.4% | |||
| Avg | 8.0% | 15.6% | |||
| Low | -4.8% | 1.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.